Lixte Biotechnology Holdings LIXT 深 滬
交易中 12-24 10:04:03 美东时间
4.01
-0.080
-1.96%
華盛通- 最 高4.0725
- 今 開4.07
- 成交量 1799股
- 最 低 4.01
- 昨 收 4.09
- 總市值 1829.12万
- 52周最高 6.26
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 0.64
- 委 比 -4.17%
- 總股本 456.14万
- 歷史最高 71.90
- 量 比 0.34
- 振 幅 1.53%
- 歷史最低 0.64
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lixte Biotechnology Announces New Registered Direct Offering
Lixte Biotechnology Holdings ( ($LIXT) ) has shared an announcement. On Decembe...
12-23 06:48
Lixte Biotechnology Holdings shares are trading lower after the company announced it commenced a $4.3 million common stock offering at $4.09 per common unit.
Lixte Biotechnology Holdings shares are trading lower after the company announc...
12-18 22:26
Lixte Biotechnology Commences $4.3M Common Stock, Pre-Funded Offering At $4.09/Common Unit
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the "Company"), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a registered direct offering
12-18 22:11
Lixte Biotechnology Holds Annual Meeting, Approves Key Issues
The latest update is out from Lixte Biotechnology Holdings ( ($LIXT) ). On Dece...
12-12 04:17
LIXTE Biotechnology Acquires Liora Technologies Europe
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a
11-25 21:33
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings, Inc. announced that its CEO, Geordan Pursglove, will present at the Spartan Capital Investor Conference 2025 in New York on November 3, 2025. The company will also hold one-on-one meetings with investors. LIXTE is developing LB-100, a first-in-class PP2A inhibitor for cancer treatment, which is currently in clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.
10-29 12:00
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings, Inc. announced its Q4 2025 priorities, including advancing its lead compound LB-100, pursuing acquisitions of complementary oncology assets, and enhancing operational readiness. The company is in advanced negotiations for potential transactions aligned with its strategic goals.
10-16 12:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Lixte Biotechnology Invests $2.6M in Cryptocurrencies
The latest announcement is out from Lixte Biotechnology Holdings ( ($LIXT) ). O...
09-12 01:47
LIXTE Biotechnology makes $2.6M initial purchase of digital currency
LIXTE Biotechnology (NASDAQ:LIXT) said on Wednesday that it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions. The company purc...
09-11 04:17
